1

2
Jeffrey T Billheimer, Peter J Gillies, C Anne Higley, Thomas P Maduskuie Jr, Ruth R Wexler: Use of imidazoles for the treatment of atherosclerosis. Du Pont Merck Pharmaceutical Company, Gildo E Fato, Annette L Richter, November 24, 1992: US05166214 (16 worldwide citation)

This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents or antiatherosclerotic.


3
Thomas P Maduskuie Jr: Antihypercholesterolemic 2-substituted imidazoles. Du Pont Merck Pharmaceutical Company, Gildo E Fato, January 12, 1993: US05179117 (10 worldwide citation)

The compounds of the described invention are potent ACAT inhibitors and are useful in pharmaceutical compositions for the treatment of atherosclerosis and have the formulas: ##STR1## when Q is a double bond wherein: R.sup.1 and R.sup.2 are each H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.10 cycloalkyl ...


4
Zhonghui Lu, Thomas P Maduskuie Jr, Matthew E Voss, Chu Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco: Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α. Bristol Myers Squibb Pharma Company, Jing G Sun, David H Vance, January 10, 2006: US06984648 (8 worldwide citation)

The present application describes novel cyclic β-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables ...


5

6

7
Jingwu Duan, Carl P Decicco, Zelda R Wasserman, Thomas P Maduskuie Jr: Lactam metalloprotease inhibitors. E I du Pont de Nemours and Company, David H Vance, May 2, 2000: US06057336 (7 worldwide citation)

The present application describes novel lactams and derivatives thereof of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein rings ring B is a 4-8 membered cyclic amide containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprote ...


8
Jeffrey T Billheimer, Peter J Gillies, C Anne Higley, Thomas P Maduskuie Jr, Ruth R Wexler: Imidazoles for the treatment of atherosclerosis. The Du Pont Merck Pharmaceutical Company, Gildo E Fato, June 7, 1994: US05318984 (7 worldwide citation)

Disclosed are compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are selected independently from H, C.sub.1 -C.sub.8 unbranched alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 araalkyl, 2-, 3- or 4-pyridinyl, 2-thie ...


9
Andrew P Combs, Eddy W Yue, Richard B Sparks, Thomas P Maduskuie Jr: Tricyclic heterocycles as BET protein inhibitors. Incyte Holdings Corporation, Incyte Corporation, Fish & Richardson P C, March 22, 2016: US09290514 (4 worldwide citation)

The present invention relates to tricyclic heterocycles of Formula (I), which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.


10
Yun Long Li, Andrew P Combs, Eddy W Yue, Thomas P Maduskuie Jr, Richard B Sparks: N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors. Incyte Corporation, Fish & Richardson P C, August 4, 2015: US09096600 (3 worldwide citation)

The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based diso ...